Protein engineering is a branch of biotechnology and belongs to the field of synthetic biology. Synthetic biology views the natural world from an engineering perspective, conceiving cells as "machines" that can be designed and used to perform specific tasks. In recent years, more and more venture capital has flowed into the field of synthetic biology. According to synbiobeta statistics, in 2017, the investment in the TOP 50 investment event in this field exceeded US$1.7 billion, setting a historical record. Among them, Ginkgo Bioworks topped the list with $275 million in financing and broke into the ranks of unicorns with a valuation of more than $1 billion. Protein engineering is an emerging research science. Biotech companies working on protein engineering are like magicians. Through computer technology and bioinformatics technology, they enable humans to freely design, transform, and create entirely new proteins for different uses. As the technology matures and costs continue to decrease, it will open a new era of development for the fields of industry, agriculture and bio-pharmaceuticals. Below are seven typical companies dedicated to protein engineering. 1. Microbiology Customized Service Provider Ginkgo Bioworks Ginkgo Bioworks, a microbiological technology custom service provider, was founded in 2008 and is headquartered in Boston, USA. In 2017, it received $275 million in Series D financing from Viking Global, Continuity Fund, Cascade Investment and General Atlantic, and has raised a total of $429 million. Ginkgo Bioworks synthesizes odors through genetic modification or even custom microbiology for perfume production in perfumery, food, cosmetics and more. Ginkgo Bioworks has built an automated biodesign system that allows scientists to spend thousands of times on genetic design prototypes. In 2017, Ginkgo and the German chemical giant Bayer Group formed a joint venture. The company will focus on producing microbial products to help nitrogen fixation and minimize the impact of agriculture on the environment by reducing the amount of chemical fertilizer used. 2. Protein Engineering "Blueprint" Arzeda Protein engineering startup Arzeda was founded in 2008 and is headquartered in Seattle, USA. In 2017, it received $15.2 million in Series A financing. The company's enzymes can be used in agriculture and manufacturing. DuPont Pioneer is one of its main customers, using new proteins to promote the rapid growth of crop seeds such as corn. Arzeda has also developed a new enzyme that synthesizes butadiene, which is usually derived from petroleum and is a key component in products such as nylon, paint and even rocket fuel. Arzeda focuses on protein engineering and develops a "blueprint" of DNA sequences necessary to create new proteins. The industrial production of the company's required molecules is done by Arzeda's customers or contract manufacturers. 3. Protein Software Company Cyrus Biotechnology Seattle Biotech software company Cyrus Biotechnology was founded in 2014 and received $9 million in financing in 2017, with a current financing of $10.4 million. The company's protein design software, called RoSeTA, has been commercialized through the University of Washington's Baker Lab. According to Cyrus, the software accelerates basic research in biotechnology, pharmaceutical and industrial biotechnology. Its cloud platform, CyrusBench, is designed to help general biotech scientists easily implement protein design and has been used to help find molecules that can cure brain cancer, break down gluten that causes celiac disease, and block various influenza strains. 4. PvP Biologics, a company that treats celiac disease Founded in California in 2016, protein engineering startup PvP Biologics received a $35 million investment from Japan's largest pharmaceutical company, Takeda. PvP Biologics is developing an oral enzyme, KumaMax, for the treatment of celiac disease in celiac disease. This new enzyme can survive the harsh conditions of the stomach and is used to prevent damage to the small intestine caused by gluten. 5. AI-based anti-flu protein company Virvio Virvio, a US biotherapeutics company, was founded in 2015 and received a $200,000 grant from the National Institutes of Health in 2017. Virvio uses AI to optimize synthetic biotherapies that are easy to manufacture, shelf stable and superior to known antibodies. The aim is to develop safer and more effective biological alternatives based on monoclonal antibodies of known efficacy. The company has created an anti-influenza micro-adhesive attached to the surface of the virus to address multiple diseases such as asthma and flu. The micro-adhesive is a small structural protein designed to meet the requirements of molecular targets and indications, as well as the ultra-stability and manufacturability of small molecule drugs. 6. AI-based protein engineering company LabGenius LabGenius in London was founded in 2012 and received $3.7 million in seed round financing in 2017. LabGenius uses artificial intelligence and robotics to develop new proteins, primarily for creating new materials such as adhesives, and even for the production of anti-wrinkle health products. The company developed an AI platform called EVA to discover high-value protein components. The company claims that the platform "breaks through the genetic design rules that support life" and can design, execute and even learn from experiments. The company has been working with a number of multinational companies to develop new biological products. 7. Unnatural amino acid protein platform Synthorx Synthorx, a synthetic biology company, was founded in 2014 and is headquartered in California. At the end of April this year, it completed a $63 million Series C financing, and has now raised a total of $79 million. We know that natural proteins are composed of 20 different amino acids. The DNA of these 20 amino acids is composed of four different bases, A, T, G, and C. The arrangement of four different bases can be Form 64 different codons. Floyd Romesberg, one of Synthorx's founders, added two new bases (codes X and Y) to the base library for building DNA. In theory, the arrangement of six different bases can form 216 different codons, eventually encoding 172 amino acids, which will bring more possibilities for life forms. Using breakthrough synthetic biotechnology, Synthorx has built a protein manufacturing platform that uses unnatural amino acids to produce proteins that cannot be produced by traditional methods on a large scale. The company also focuses on protein therapies for cancer and immune diseases. Author: Zhang Ke Foot Spa Machine,Foot Tub Spa Pedicure,Foot Bath Massager,Bubble Foot Spa Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootbath.com
